Valuation: Keymed Biosciences Inc.

Market Cap 20.54B 24.01B 3.06B 2.72B 2.54B 2.32B 4.36B 295B 4.42B 30.74B 11.9B 150B 11.49B 11.24B 482B P/E 2026 *
25.5x
P/E 2027 * 1,434x
Enterprise Value 19.41B 22.69B 2.89B 2.57B 2.4B 2.19B 4.12B 278B 4.18B 29.06B 11.25B 142B 10.86B 10.62B 455B EV / Sales 2026 *
11.5x
EV / Sales 2027 * 9.13x
Free-Float
74.84%
Yield 2026 *
-
Yield 2027 * -
1 day-3.31%
1 week+5.20%
Current month-3.31%
1 month+1.41%
3 months+5.20%
6 months+10.51%
Current year+47.52%
1 week 72.3
Extreme 72.3
82.4
1 month 71
Extreme 71
82.4
Current year 44.66
Extreme 44.66
89.75
1 year 44.66
Extreme 44.66
89.75
3 years 26.6
Extreme 26.6
89.75
5 years 16.9
Extreme 16.9
89.75
10 years 16.9
Extreme 16.9
89.75
Manager TitleAgeSince
Chief Executive Officer 52 23/04/2018
Corporate Officer/Principal 61 03/03/2021
Corporate Secretary - 29/03/2022
Director TitleAgeSince
Chairman 52 23/04/2018
Director/Board Member 61 03/03/2021
Director/Board Member 52 21/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/6/25
Moonshot Holdings Ltd.
OtherCompany 21,600,000 7.7216%
11/6/25
Moonshot Holdings Ltd.
OtherCompany 18,800,000 6.7206%
15/9/23
Moonshot Holdings Ltd.
OtherCompany 114,500 0.0409%
Change 5-day change 1-year change 3-year change Capi.($)
-3.31%+5.20%+4.16%+64.96% 3.06B
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.93%-1.35%+24.67%+78.54% 59.26B
+1.07%-0.39%+4.54%+34.84% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.79%-0.08%+48.01%+145.23% 39.55B
Weighted average by Cap. +0.02%-0.29%+57.66%+145.22%

Financials

2026 *2027 *
Net sales 1.68B 1.97B 251M 223M 208M 190M 357M 24.12B 362M 2.52B 975M 12.29B 941M 920M 39.46B 2.15B 2.51B 320M 284M 266M 242M 456M 30.78B 462M 3.21B 1.24B 15.68B 1.2B 1.17B 50.35B
Net income 672M 786M 100M 88.98M 83.21M 75.83M 143M 9.65B 145M 1.01B 390M 4.91B 376M 368M 15.78B -14.18M -16.57M -2.11M -1.88M -1.75M -1.6M -3.01M -203M -3.05M -21.22M -8.22M -104M -7.93M -7.76M -333M
Net Debt -1.12B -1.31B -167M -149M -139M -127M -238M -16.11B -242M -1.68B -651M -8.2B -628M -614M -26.35B -935M -1.09B -139M -124M -116M -105M -199M -13.41B -201M -1.4B -542M -6.83B -523M -512M -21.94B
Logo Keymed Biosciences Inc.
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
1,768
Date Price Change Volume
02/10/26 HKD 78.85 -3.31% 490,000
30/09/26 HKD 81.55 +2.45% 2,630,600
29/09/26 HKD 79.60 +8.82% 4,260,252
28/09/26 HKD 73.15 -2.40% 2,244,500
25/09/26 HKD 74.95 +1.22% 600,500
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
69.71CNY
Average target price
88.83CNY
Spread / Average Target
+27.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2162 Stock